As a core element in the molecular machinery of selective autophagy, this far more detailed insight into the membrane docking steps of LC3 will undoubtedly facilitate the therapeutic targeting of autophagy in Parkinson’s disease and other neurodegenerative diseases. This evidence concerns the gene MAP1LC3A and neurodegenerative disease.